Prevalence, Treatment Patterns, and Characteristics of US Adults with Confirmed or at Risk for Growth Hormone Deficiency

IF 3.4 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Advances in Therapy Pub Date : 2025-04-22 DOI:10.1007/s12325-025-03188-6

Andrew R. Hoffman, Subhara Raveendran, Janna Manjelievskaia, Allison S. Komirenko, Isabelle Winer, Jennifer Cheng, Machaon Bonafede, Jessamine P. Winer-Jones, Paul Miner, Alden R. Smith

{"title":"Prevalence, Treatment Patterns, and Characteristics of US Adults with Confirmed or at Risk for Growth Hormone Deficiency","authors":"Andrew R. Hoffman, Subhara Raveendran, Janna Manjelievskaia, Allison S. Komirenko, Isabelle Winer, Jennifer Cheng, Machaon Bonafede, Jessamine P. Winer-Jones, Paul Miner, Alden R. Smith","doi":"10.1007/s12325-025-03188-6","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Adult growth hormone deficiency (GHD) is an endocrine disorder associated with increased morbidity and poor quality of life. The purpose of this study was to describe the clinical characteristics, treatment patterns, and prevalence of individuals at risk for adult GHD and individuals with confirmed adult GHD in the United States (US).</p><h3>Methods</h3><p>Using Veradigm Network electronic health records linked to claims, this study identified adults with a high likelihood of adult GHD based on having ≥ 1 of the following between January 1, 2017 and December 31, 2021: diagnosis of hypopituitarism or ≥ 1 related condition, such as Cushing disease, ≥ 3 pituitary hormone deficiencies other than GHD, ≥ 3 pituitary hormone treatments other than growth hormone (GH), or ≥ 1 prescription for GH. Index date was the earliest qualifying event. Individuals were stratified by GH level on or before index date: confirmed adult GHD (< 3 ng/mL), at risk for adult GHD (no test result), ruled-out (≥ 3 ng/mL).</p><h3>Results</h3><p>US prevalence of adult GHD was estimated to be between 0.2 (confirmed) and 37.0 (confirmed + at-risk) per 100,000. Among 268 individuals with confirmed adult GHD and 54,310 at risk for adult GHD, mean age was 50 years old, and a majority were female. GH treatment was initiated in 9.7% of confirmed individuals and 3.1% of those at risk for adult GHD. Among confirmed and at-risk individuals, prevalence of endocrine-related conditions was higher in treated individuals, whereas prevalence of several metabolic and cardiovascular comorbidities was higher in those untreated. Only 32.2% of individuals who initiated treatment during the follow-up period were persistent until the end of follow-up.</p><h3>Conclusions</h3><p>Our findings report US prevalence of adult GHD and suggest that adult GHD is commonly underdiagnosed in the US. Factors contributing to low rates of adult GHD diagnosis and treatment warrant further research.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 6","pages":"2853 - 2873"},"PeriodicalIF":3.4000,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-025-03188-6.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12325-025-03188-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Adult growth hormone deficiency (GHD) is an endocrine disorder associated with increased morbidity and poor quality of life. The purpose of this study was to describe the clinical characteristics, treatment patterns, and prevalence of individuals at risk for adult GHD and individuals with confirmed adult GHD in the United States (US).

Methods

Using Veradigm Network electronic health records linked to claims, this study identified adults with a high likelihood of adult GHD based on having ≥ 1 of the following between January 1, 2017 and December 31, 2021: diagnosis of hypopituitarism or ≥ 1 related condition, such as Cushing disease, ≥ 3 pituitary hormone deficiencies other than GHD, ≥ 3 pituitary hormone treatments other than growth hormone (GH), or ≥ 1 prescription for GH. Index date was the earliest qualifying event. Individuals were stratified by GH level on or before index date: confirmed adult GHD (< 3 ng/mL), at risk for adult GHD (no test result), ruled-out (≥ 3 ng/mL).

Results

US prevalence of adult GHD was estimated to be between 0.2 (confirmed) and 37.0 (confirmed + at-risk) per 100,000. Among 268 individuals with confirmed adult GHD and 54,310 at risk for adult GHD, mean age was 50 years old, and a majority were female. GH treatment was initiated in 9.7% of confirmed individuals and 3.1% of those at risk for adult GHD. Among confirmed and at-risk individuals, prevalence of endocrine-related conditions was higher in treated individuals, whereas prevalence of several metabolic and cardiovascular comorbidities was higher in those untreated. Only 32.2% of individuals who initiated treatment during the follow-up period were persistent until the end of follow-up.

Conclusions

Our findings report US prevalence of adult GHD and suggest that adult GHD is commonly underdiagnosed in the US. Factors contributing to low rates of adult GHD diagnosis and treatment warrant further research.

查看原文本刊更多论文

美国成人生长激素缺乏症的患病率、治疗模式和特征

成人生长激素缺乏症（GHD）是一种与发病率增加和生活质量差相关的内分泌紊乱。本研究的目的是描述美国成人GHD风险个体和确诊成人GHD个体的临床特征、治疗模式和患病率。方法：使用Veradigm网络与索赔相关的电子健康记录，本研究确定了在2017年1月1日至2021年12月31日期间具有以下≥1项的成人GHD高可能性的成年人：垂体功能减退或≥1种相关疾病，如库欣病，≥3种除GHD以外的垂体激素缺乏，≥3种除生长激素（GH）以外的垂体激素治疗，或≥1种GH处方。指数日是最早的资格赛。根据指数日期当日或之前的GH水平对个体进行分层：确诊成人GHD(结果：美国成人GHD患病率估计在每10万人中0.2（确诊）至37.0（确诊+高危）之间。在268例确诊成人GHD和54,310例有成人GHD风险的个体中，平均年龄为50岁，大多数为女性。9.7%的确诊患者和3.1%的成人GHD高危患者接受了GH治疗。在确诊和高危人群中，接受治疗的人群中内分泌相关疾病的患病率较高，而未接受治疗的人群中几种代谢和心血管合并症的患病率较高。在随访期间开始治疗的个体中，只有32.2%的人坚持到随访结束。结论：我们的研究结果报告了美国成人GHD的患病率，并表明成人GHD在美国通常被低估。导致成人GHD诊断率和治疗率低的因素值得进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Therapy 医学-药学

CiteScore

7.20

自引率

2.60%

发文量

353

审稿时长

6-12 weeks

期刊介绍： Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.